CMV hyperimmune globulin as salvage therapy for recurrent or refractory CMV infection in children undergoing hematopoietic stem cell transplantation

Frontiers in Pediatrics

Pediatrics

Laura Alonso¹  Melissa Panesso¹  María Isabel Benítez-Carabante¹  Cristina Diaz-de-Heredia¹  María Luz Uría¹  Juliana Esperalba²  Natalia Mendoza-Palomar³  Maria Oliveras⁴  Berta Renedo⁴ 

[1] Division of Pediatric Oncology and Haematology, Hospital Universitari Vall d’Hebron, Barcelona, Spain;Institut de Recerca Vall d’Hebron, Barcelona, Spain;Institut de Recerca Vall d’Hebron, Barcelona, Spain;Microbiology Division, Hospital Universitari Vall d’Hebron, Barcelona, Spain;Institut de Recerca Vall d’Hebron, Barcelona, Spain;Pediatric Infectious Diseases and Immunodeficiencies Unit, Hospital Universitari Vall d’Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain;Institut de Recerca Vall d’Hebron, Barcelona, Spain;Pharmacy Division, Hospital Universitari Vall d’Hebron, Barcelona, Spain;

关键词: cytomegalovirus;    hematopoietic stem cell transplantation;    children;    CMV hyperimmune globulin;    salvage therapy;   

DOI  :  10.3389/fped.2023.1197828

 received in 2023-03-31, accepted in 2023-07-06,  发布年份 2023

来源: Frontiers

【 摘 要 】

Cytomegalovirus (CMV) is a major cause of allogeneic hematopoietic stem cell transplant (HSCT)-related morbidity and mortality. Treatment failure continues to be a major issue in patients with CMV infection due to both drug resistance and intolerance. This single-center brief retrospective analysis of a case series aims to investigate the safety and efficacy of CMV-hyperimmune globulin as salvage therapy for CMV infection in children undergoing HSCT. Fifteen pediatric patients received human CMV-specific immunoglobulin (CMVIG) between July 2018 and December 2021 as a salvage therapy for refractory or recurrent CMV infection. At the time of CMVIG prescription, eight children presented with recurrent CMV infection and seven with refractory CMV infection. The overall response rate was 67% at 50 days from the CMVIG administration [95% confidence interval (CI): 44–88]. Overall survival (OS) from CMVIG administration at 100 days was 87% (95% CI: 56–96), and OS from HSCT at 1 year was 80% (95% CI: 50–93). Four patients died, three unrelated to CMV infection and one due to CMV pneumonia. CMVIG as salvage therapy was well tolerated, and no infusion-related adverse events were observed.

【 授权许可】

Unknown   
© 2023 Panesso, Uría, Renedo, Esperalba, Benítez-Carabante, Mendoza-Palomar, Alonso, Oliveras and Diaz-de-Heredia.